Press release
Dexcom Showcases Extensive Clinical Data at ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People With Type 2 Diabetes
Dexcom unveils more clinical data reaffirming the benefits of Dexcom CGM use among people with Type 2 diabetes than at any previous ADA conference. ADA
About this update from Dexcom, Inc.
[{"type":"text","content":"\n\nDexcom unveils more clinical data reaffirming the benefits of Dexcom CGM use among people with Type 2 diabetes than at any previous ADA conference.\n\n\n\nADA conference presentations reiterate the advantages of Dexcom CGM use alongside incretin therapies such as GLP-1s.1,2\n\n\n\nNew Dexcom G7 automated insulin delivery integrations* further solidify the company’s undisputed leadership in CGM connectivity.\n\n\n\nRecently released Dexcom G7 app updates, including Direct to Apple Watch,† demonstrate relentless commitment to innovation and improving user experience.\n\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nDexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM use among people with Type 2 diabetes, the launch of the Omnipod 5 Automated Insulin Delivery System with Dexcom G7 and its relentless commitment to innovation at the 84th Scientific Sessions of the American Diabetes Association conference held June 21–24, 2024, in Orlando.\n\n\nDexcom: The CGM brand for people with Type 2 diabetes, prediabetes and those using GLP-1s\n\n\nThis year at ADA, Dexcom is presenting more data on Dexcom CGM use among people with Type 2 diabetes than ever before. This data shows clinically meaningful decreases in A1C and increases in time in range for Dexcom CGM users with Type 2 diabetes both on insulin and not on insulin.3-5\n\n\nAdditionally, studies presented at the conference demonstrate Dexcom CGM use by people with Type 2 diabetes not on insulin is associated with improved A1C independent of anti-diabetes medication, and there may be further benefits of CGM for this population when used in combination with therapies such as GLP-1s.1 As the use of GLP-1s continues to grow, data continues to show people with Type 2 diabetes on GLP-1s are more likely to use CGM after starting the medication.2\n\n\nGoing beyond Type 2 diabetes, another study presented at ADA demonstrates Dexcom CGM is a valuable behavior modification tool for people with prediabetes.6 In this study, Dexcom CGM use was associated with improved self-reported psychosocial health and self-care behaviors in participants with prediabetes including perceived benefits related to eating, physical activity, weight, blood pressure, worry, energy levels and healthcare provider...